Company intelligence / Profile preview

Novonesis

Ownership: Public · NSIS B
Employees: ~10000
Development stage: Other

Overview

Novonesis is a global leader in biosolutions following the 2024 merger of Novozymes and Chr. Hansen. It delivers commercial-scale enzyme, protein, and microbial products across more than 30 industries including food & beverage, agriculture, human health/nutrition, household care, biofuels/energy production. The company reported strong financial results in 2024 with organic sales growth of 8% and an adjusted EBITDA margin over 36%

Therapeutic areas: GastroenterologyMetabolic DisordersOther
Modalities: EnzymeMicrobial therapy (including probiotics, prebiotics)Recombinant protein
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Novonesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novonesis.

Explore the full profile